Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study will determine the frequency of adverse events (side effects) in patients with
relapsed or refractory small cell lung cancer (SCLC) when given nivolumab and irinotecan
together followed by nivolumab maintenance. This study will test the safety of the study
treatments when given together and see what effect (good or bad) it has on participants and
their cancer.